Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 102 clinical trials
featured
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma

. Researchers want to see if this therapy fights kidney cancer cells. Metastatic renal cell carcinoma (RCC) is an incurable condition. Current therapy for this disease consists of the serial administration

metastatic cancer
clear cell renal cell carcinoma
carcinoma
primary cancer
clear cell carcinoma
  • 144 views
  • 22 Dec, 2020
  • 1 location
featured
PHASE III RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL EVALUATING THE USE OF ADJUVANT ENDOCRINE THERAPY +/- ONE YEAR OF EVEROLIMUS IN PATIENTS WITH HIGH-RISK, HORMONE RECEPTOR-POSITIVE AND HER2/NEU NEGATIVE BREAST CANCER.

PHASE III RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL EVALUATING THE USE OF ADJUVANT ENDOCRINE THERAPY +/- ONE YEAR OF EVEROLIMUS IN PATIENTS WITH HIGH-RISK, HORMONE RECEPTOR-POSITIVE AND HER2/NEU NEGATIVE BREAST CANCER.

endocrine therapy
erbb2
hormone therapy
HER2
breast cancer
  • 220 views
  • 24 Nov, 2020
  • 1 location
featured
Alliance A031203: Randomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma

Metastatic Renal Cell Carcinoma

  • 186 views
  • 08 Nov, 2020
  • 1 location
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC

SUNNIFORECAST (Sunitinib vs. Nivolumab + Ipilimumab as First line treatment Of REnal cell CAncer of non-clear cell SubTypes) is a Phase II, randomized, open-label investigator initiated trial (IIT) of Nivolumab (BMS-936558) combined with Ipilimumab vs standard of care in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell …

sunitinib
nivolumab
clear cell renal cell carcinoma
metastasis
cancer
  • 116 views
  • 08 Jun, 2020
  • 40 locations
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with …

  • 2 views
  • 05 Dec, 2020
  • 67 locations
Immunochemotherapy for Metastatic Renal Cell Carcinoma

Immunochemotherapy consisting of IL-2, INF-A, and VBL and 5FU is regarded as the treatment of choice in metastatic renal cell carcinoma. During the period 1996-2000, we evaluated the

  • 25 views
  • 07 Nov, 2020
  • 1 location
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

interleukin-2 works in treating patients with metastatic kidney cancer.

carcinoma
arrhythmia
metastatic renal cell carcinoma
diabetes
tumor cells
  • 17 views
  • 07 Nov, 2020
  • 2 locations
A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma

and metastatic renal cell carcinoma. This study consists of two parts: Dose Escalation and Dose Expansion. During the dose escalation phase, participants will be sequentially enrolled in a standard 3

  • 8 views
  • 12 Dec, 2020
  • 1 location
Multi-center Trial of ESK981 in Combination With Nivolumab in Patients With Metastatic Renal Cell Carcinoma

The objective of the trial is to determine the clinical efficacy of ESK981 in combination with nivolumab therapy in patients with metastatic renal cell carcinoma.

nivolumab
vascular endothelial growth factor
measurable disease
systemic therapy
vegf
  • 0 views
  • 28 Sep, 2020
  • 1 location
Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors

Aim of the FavorAx study is to evaluate preliminary efficacy and safety of Axitinib in metastatic renal cell carcinoma patients with favorable IMDC prognostic factors who had progressed on

sunitinib
carcinoma
measurable disease
axitinib
pazopanib
  • 23 views
  • 08 Nov, 2020
  • 1 location